000130583 001__ 130583
000130583 005__ 20240228143445.0
000130583 0247_ $$2doi$$a10.1080/2162402X.2016.1240858
000130583 0247_ $$2pmid$$apmid:28123877
000130583 0247_ $$2pmc$$apmc:PMC5214097
000130583 0247_ $$2ISSN$$a2162-4011
000130583 0247_ $$2ISSN$$a2162-402X
000130583 037__ $$aDKFZ-2017-05662
000130583 041__ $$aeng
000130583 082__ $$a610
000130583 1001_ $$00000-0002-4700-272X$$aSonner, Jana K$$b0$$eFirst author
000130583 245__ $$aThe stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas.
000130583 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2016
000130583 3367_ $$2DRIVER$$aarticle
000130583 3367_ $$2DataCite$$aOutput Types/Journal article
000130583 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524641022_9610
000130583 3367_ $$2BibTeX$$aARTICLE
000130583 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130583 3367_ $$00$$2EndNote$$aJournal Article
000130583 520__ $$aTryptophan metabolism is a key process that shapes the immunosuppressive tumor microenvironment. The two rate-limiting enzymes that mediate tryptophan depletion, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO), have moved into the focus of research and inhibitors targeting IDO and TDO have entered clinical trials. Local tryptophan depletion is generally viewed as the crucial immunosuppressive mechanism. In T cells, the kinase general control non-derepressible 2 (GCN2) has been identified as a molecular sensor of tryptophan deprivation. GCN2 activation by tryptophan depletion induces apoptosis and mitigates T cell proliferation. Here, we investigated whether GCN2 attenuates tumor rejection in experimental B16 melanoma using T cell-specific Gcn2 knockout mice. Our data demonstrate that GCN2 in T cells did not affect immunity to B16 tumors even when animals were treated with antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA4). GCN2-deficient gp100 TCR-transgenic T cells were equally effective as wild-type pmel T cells against gp100-expressing B16 melanomas after adoptive transfer and gp100 peptide vaccination. Even augmentation of tumoral tryptophan metabolism in B16 tumors by lentiviral overexpression of Tdo did not differentially affect GCN2-proficient vs. GCN2-deficient T cells in vivo. Importantly, GCN2 target genes were not upregulated in tumor-infiltrating T cells. MALDI-TOF MS imaging of B16 melanomas demonstrated maintenance of intratumoral tryptophan levels despite high tryptophan turnover, which prohibits a drop in tryptophan sufficient to activate GCN2 in tumor-infiltrating T cells. In conclusion, our results do not suggest that suppression of antitumor immune responses by tryptophan metabolism is driven by local tryptophan depletion and subsequent GCN2-mediated T cell anergy.
000130583 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130583 588__ $$aDataset connected to CrossRef, PubMed,
000130583 7001_ $$0P:(DE-He78)c1a5de00fb2617c5c43d8f30f6e0cd2b$$aDeumelandt, Katrin$$b1$$udkfz
000130583 7001_ $$0P:(DE-He78)8ad8a02ad786e6e86cbc5ccdbb661da7$$aOtt, Martina$$b2$$udkfz
000130583 7001_ $$aThomé, Carina M$$b3
000130583 7001_ $$0P:(DE-He78)0309269304ea1caf7e1d2dc870e25a39$$aRauschenbach, Katharina$$b4$$udkfz
000130583 7001_ $$0P:(DE-HGF)0$$aSchulz, Sandra$$b5
000130583 7001_ $$aMunteanu, Bogdan$$b6
000130583 7001_ $$0P:(DE-He78)0a6d2d4e161256f6ce1ca4b630bcf246$$aMohapatra, Soumya Ranjan$$b7$$udkfz
000130583 7001_ $$0P:(DE-He78)87ea42734796b456321cc1eb6df7361f$$aAdam, Isabell$$b8$$udkfz
000130583 7001_ $$0P:(DE-He78)24f65e08387eafe8f511b710e366fdf4$$aHofer, Ann-Cathrin$$b9$$udkfz
000130583 7001_ $$0P:(DE-He78)f0638edf1d3f61c0d7ebb587f511733f$$aFeuerer, Markus$$b10$$udkfz
000130583 7001_ $$0P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aOpitz, Christiane$$b11$$udkfz
000130583 7001_ $$0P:(DE-HGF)0$$aHopf, Carsten$$b12
000130583 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b13$$udkfz
000130583 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b14$$eLast author$$udkfz
000130583 773__ $$0PERI:(DE-600)2645309-5$$a10.1080/2162402X.2016.1240858$$gVol. 5, no. 12, p. e1240858 -$$n12$$pe1240858 -$$tOncoImmunology$$v5$$x2162-402X$$y2016
000130583 909CO $$ooai:inrepo02.dkfz.de:130583$$pVDB
000130583 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-4700-272X$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c1a5de00fb2617c5c43d8f30f6e0cd2b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8ad8a02ad786e6e86cbc5ccdbb661da7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0309269304ea1caf7e1d2dc870e25a39$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a6d2d4e161256f6ce1ca4b630bcf246$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)87ea42734796b456321cc1eb6df7361f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24f65e08387eafe8f511b710e366fdf4$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0638edf1d3f61c0d7ebb587f511733f$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000130583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000130583 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130583 9141_ $$y2016
000130583 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOIMMUNOLOGY : 2015
000130583 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130583 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130583 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130583 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130583 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130583 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130583 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130583 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOIMMUNOLOGY : 2015
000130583 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000130583 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x1
000130583 9201_ $$0I:(DE-He78)D100-20160331$$kD100$$lImmuntoleranz$$x2
000130583 9201_ $$0I:(DE-He78)G161-20160331$$kG161$$lBrain Cancer Metabolism$$x3
000130583 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000130583 980__ $$ajournal
000130583 980__ $$aVDB
000130583 980__ $$aI:(DE-He78)G160-20160331
000130583 980__ $$aI:(DE-He78)G370-20160331
000130583 980__ $$aI:(DE-He78)D100-20160331
000130583 980__ $$aI:(DE-He78)G161-20160331
000130583 980__ $$aI:(DE-He78)L101-20160331
000130583 980__ $$aUNRESTRICTED